UK markets closed
NIKKEI 225
39,069.68 +282.30 (+0.73%) HANG SENG
19,636.22 +82.61 (+0.42%) CRUDE OIL
79.60 -0.46 (-0.57%) GOLD FUTURES
2,431.10 +13.70 (+0.57%) DOW
39,978.90 -24.69 (-0.06%) Bitcoin GBP
53,601.32 +1,046.61 (+1.99%)
MRNA Oct 2024 90.000 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 12:16PM EDT. Market open.
| Previous close | 34.03 |
| Open | 53.90 |
| Bid | 54.10 |
| Ask | 54.75 |
| Strike | 90.00 |
| Expiry date | 2024-10-18 |
| Day's range | 53.90 - 53.90 |
| Contract range | N/A |
| Volume | |
| Open interest | 127 |
BenzingaEuropean Patent Office Sides with Moderna In COVID-19 Vaccine Patent Dispute With Pfizer/BioNTech
Moderna Inc (NASDAQ:MRNA) has reportedly achieved a significant victory at the European Patent Office (EPO) in its ongoing legal battle with Pfizer Inc (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) over the Covid-19 vaccine. The EPO’s Opposition Division upheld the validity of one of Moderna’s crucial patents, boosting the mRNA vaccine maker’s efforts to reclaim pandemic profits from its competitors, the Financial Times reports. Although Pfizer has nine months to appeal the decision, the EPO’s writte
ZacksThe Zacks Analyst Blog Highlights Novavax, Sanofi, Fulcrum Therapeutics, Moderna and Bristol Myers
Novavax, Sanofi, Fulcrum Therapeutics, Moderna and Bristol Myers are included in this Analyst Blog.
ZacksBiotech Stock Roundup: NVAX, FULC Up on Deals With SNY, Updates From MRNA, BMY
Novavax, Inc (NVAX) and Fulcrum Therapeutics, Inc (FULC) are in the spotlight following license agreements with pharma giant Sanofi.
© 2024 Yahoo. All rights reserved.